Q2 EPS Estimates for Globus Medical Lifted by Zacks Research

Globus Medical, Inc. (NYSE:GMED) – Equities research analysts at Zacks Research lifted their Q2 2025 EPS estimates for shares of Globus Medical in a research note issued on Tuesday, January 21st. Zacks Research analyst R. Department now expects that the medical device company will earn $0.86 per share for the quarter, up from their previous estimate of $0.85. The consensus estimate for Globus Medical’s current full-year earnings is $2.98 per share. Zacks Research also issued estimates for Globus Medical’s Q4 2025 earnings at $0.95 EPS and FY2026 earnings at $3.97 EPS.

A number of other research firms have also commented on GMED. Wells Fargo & Company boosted their price objective on Globus Medical from $88.00 to $95.00 and gave the stock an “overweight” rating in a research note on Wednesday, December 11th. Roth Mkm upped their price target on shares of Globus Medical from $100.00 to $115.00 and gave the stock a “buy” rating in a research report on Tuesday, December 17th. Stifel Nicolaus raised their price objective on shares of Globus Medical from $80.00 to $92.00 and gave the company a “buy” rating in a research report on Wednesday, November 6th. BTIG Research upped their target price on shares of Globus Medical from $87.00 to $91.00 and gave the stock a “buy” rating in a research report on Thursday, December 12th. Finally, Truist Financial increased their price target on shares of Globus Medical from $85.00 to $90.00 and gave the company a “hold” rating in a research note on Wednesday, December 18th. Four analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $96.91.

Globus Medical Price Performance

NYSE GMED opened at $93.25 on Wednesday. The stock’s 50 day simple moving average is $84.43 and its 200 day simple moving average is $76.33. Globus Medical has a one year low of $49.33 and a one year high of $93.67. The firm has a market cap of $12.70 billion, a PE ratio of 139.18, a price-to-earnings-growth ratio of 1.73 and a beta of 1.19.

Globus Medical (NYSE:GMED) last issued its quarterly earnings data on Tuesday, November 5th. The medical device company reported $0.83 earnings per share for the quarter, topping the consensus estimate of $0.65 by $0.18. The firm had revenue of $625.71 million for the quarter, compared to analysts’ expectations of $604.69 million. Globus Medical had a net margin of 3.69% and a return on equity of 9.98%. The company’s quarterly revenue was up 63.1% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.57 earnings per share.

Insider Buying and Selling at Globus Medical

In other news, CFO Keith W. Pfeil sold 14,167 shares of the company’s stock in a transaction dated Friday, January 10th. The stock was sold at an average price of $88.29, for a total value of $1,250,804.43. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Daniel T. Scavilla sold 60,000 shares of Globus Medical stock in a transaction that occurred on Wednesday, November 6th. The stock was sold at an average price of $80.02, for a total transaction of $4,801,200.00. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 81,667 shares of company stock valued at $6,674,554. 18.54% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Globus Medical

Hedge funds have recently bought and sold shares of the company. American Century Companies Inc. increased its position in shares of Globus Medical by 5.7% in the 2nd quarter. American Century Companies Inc. now owns 26,625 shares of the medical device company’s stock valued at $1,824,000 after buying an additional 1,442 shares in the last quarter. Envestnet Asset Management Inc. grew its stake in Globus Medical by 5.2% in the second quarter. Envestnet Asset Management Inc. now owns 266,207 shares of the medical device company’s stock valued at $18,232,000 after acquiring an additional 13,221 shares during the period. Vanguard Personalized Indexing Management LLC increased its holdings in shares of Globus Medical by 16.1% in the second quarter. Vanguard Personalized Indexing Management LLC now owns 11,664 shares of the medical device company’s stock worth $798,000 after acquiring an additional 1,616 shares in the last quarter. Hsbc Holdings PLC raised its position in shares of Globus Medical by 21.3% during the second quarter. Hsbc Holdings PLC now owns 6,634 shares of the medical device company’s stock worth $454,000 after purchasing an additional 1,163 shares during the period. Finally, Intech Investment Management LLC bought a new position in shares of Globus Medical during the 2nd quarter valued at about $359,000. 95.16% of the stock is currently owned by institutional investors and hedge funds.

Globus Medical Company Profile

Globus Medical, Inc, a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative and congenital conditions, deformity, tumors, and trauma injuries; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives.